338840 — Y Biologics Balance Sheet
0.000.00%
- KR₩147bn
- KR₩132bn
- KR₩3bn
Annual balance sheet for Y Biologics, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|
Period Length: | — | — | — |
Source: | Annual Audited Accounts | Annual Audited Accounts | ARS |
Standards: | — | — | IFRS |
Status: | Final | Final | Final |
Cash and Equivalents | |||
Short Term Investments | |||
Cash and Short Term Investments | 16,948 | 12,983 | 20,898 |
Net Total Accounts Receivable | |||
Net Total Receivables | 2,083 | 895 | 639 |
Prepaid Expenses | |||
Total Other Current Assets | |||
Total Current Assets | 19,845 | 18,034 | 21,763 |
Gross Property, Plant And Equipment | |||
Accumulated Depreciation | |||
Net Property, Plant And Equipment | 16,824 | 10,801 | 8,009 |
Net Intangible Assets | |||
Long Term Investments | |||
Other Long Term Assets | |||
Total Assets | 38,245 | 29,323 | 30,294 |
Accounts Payable | |||
Payable / Accrued | |||
Accrued Expenses | |||
Notes Payable / Short Term Debt | |||
Current Portion of Long Term Debt / Capital Leases | |||
Total Other Current Liabilities | |||
Total Current Liabilities | 6,209 | 16,195 | 5,508 |
Long Term Debt | |||
Capital Lease Obligations | |||
Total Long Term Debt | |||
Total Debt | |||
Total Other Liabilities | |||
Total Liabilities | 9,803 | 17,029 | 6,886 |
Common Stock | |||
Additional Paid In Capital | |||
Retained Earnings (Accumulated Deficit) | |||
Other Equity | |||
Total Equity | 28,441 | 12,293 | 23,408 |
Total Liabilities & Shareholders' Equity | 38,245 | 29,323 | 30,294 |
Total Common Shares Outstanding | |||
Total Preferred Shares Outstanding |